en
Scientific article
Open access
English

Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease

Published inJournal of Alzheimer's Disease, vol. 69, no. 1, p. 49-58
Publication date2019
Abstract

Assessment of human brain atrophy in temporal regions using magnetic resonance imaging (MRI), resting state functional MRI connectivity in the left parietal cortex, and limbic electroencephalographic (rsEEG) rhythms as well as plasma amyloid peptide 42 (Aβ42) has shown that each is a promising biomarker of disease progression in amnestic mild cognitive impairment (aMCI) patients with prodromal Alzheimer's disease (AD). However, the value of their combined use is unknown.

Keywords
  • Alzheimer's disease
  • Biomarker matrices
  • Clinical trial
  • Magnetic resonance imaging
  • Mild cognitive impairment
Citation (ISO format)
MARIZZONI, Moira et al. Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease. In: Journal of Alzheimer’s Disease, 2019, vol. 69, n° 1, p. 49–58. doi: 10.3233/JAD-181016
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal1387-2877
237views
322downloads

Technical informations

Creation07/10/2020 2:57:00 PM
First validation07/10/2020 2:57:00 PM
Update time03/15/2023 10:28:59 PM
Status update03/15/2023 10:28:58 PM
Last indexation10/19/2023 1:23:54 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack